Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.

Correction to Lancet Respir Med 2021; published online Feb 26. [https://doi.org/10.1016/S2213-2600\(20\)30448-3](https://doi.org/10.1016/S2213-2600(20)30448-3)

Wallis RS, Ginindza S, Beattie T, et al. Adjunctive host-directed therapies for pulmonary tuberculosis: a prospective, open-label, phase 2, randomised controlled trial. *Lancet Respir Med* 2021; published online Feb 26. [https://doi.org/10.1016/S2213-2600\(20\)30448-3](https://doi.org/10.1016/S2213-2600(20)30448-3)—In the author list, affiliations, and Contributors section of this Article, details for an additional author (Modulakgotla Sebe) have been added. The following affiliation for Trevor Beattie has also been added: “Department of Interdisciplinary Social Sciences, Utrecht University, Utrecht, Netherlands”. These corrections have been made to the online version as of April 19, 2021, and will be made to the printed version.

Correction to Lancet Respir Med 2021; published online April 19. [https://doi.org/10.1016/S2213-2600\(21\)00096-5](https://doi.org/10.1016/S2213-2600(21)00096-5)

Lebreton G, Schmidt M, Ponnaiah M, et al. Extracorporeal membrane oxygenation network organisation and clinical outcomes during the COVID-19 pandemic in Greater Paris, France: a multicentre cohort study. *Lancet Respir Med* 2021; published online April 19. [https://doi.org/10.1016/S2213-2600\(21\)00096-5](https://doi.org/10.1016/S2213-2600(21)00096-5)—In the Summary of this Article, the second-to-last sentence of the Findings should have said “lower pre-ECMO renal component”. This correction has been made to the online version as of April 26, 2021, and will be made to the printed Article.

Correction to Lancet Respir Med 2021; published online April 9. [https://doi.org/10.1016/S2213-2600\(21\)00160-0](https://doi.org/10.1016/S2213-2600(21)00160-0)

Ramakrishnan S, Nicolau DV Jr, Langford B, et al. Inhaled budesonide in the treatment of early COVID-19 (STOIC): a phase 2, open-label, randomised controlled trial. *Lancet Respir Med* 2021; published online April 9. [https://doi.org/10.1016/S2213-2600\(21\)00160-0](https://doi.org/10.1016/S2213-2600(21)00160-0)—In this Article, the findings section of the summary should have read, “For the per-protocol population (n=139), the primary outcome occurred in ten (14%) of 70 participants in the usual care group and one (1%) of 69 participants in the budesonide group”. Additionally, in the Summary and Results, the dose of budesonide should have been 400 µg per actuation, to a total dose (two puffs to be taken twice per day) of 1600 µg. These corrections have been made to the online version as of April 14, 2021, and will be made to the printed version.

Correction to Lancet Respir Med 2021; published online April 9. [https://doi.org/10.1016/S2213-2600\(21\)00171-5](https://doi.org/10.1016/S2213-2600(21)00171-5)

Agusti A, Torres F, Faner R. Early treatment with inhaled budesonide to prevent clinical deterioration in patients with COVID-19. *Lancet Respir Med* 2021; published online April 9. [https://doi.org/10.1016/S2213-2600\(21\)00171-5](https://doi.org/10.1016/S2213-2600(21)00171-5)—In this Comment, the dose of budesonide should have been 400 µg per actuation, to a total dose (two puffs to be taken twice per day) of 1600 µg. This correction has been made to the online version as of April 14, 2021, and will be made to the printed version.

Published Online
April 19, 2021
[http://dx.doi.org/10.1016/S2213-2600\(21\)00204-6](http://dx.doi.org/10.1016/S2213-2600(21)00204-6)

Published Online
April 14, 2021
[http://dx.doi.org/10.1016/S2213-2600\(21\)00181-8](http://dx.doi.org/10.1016/S2213-2600(21)00181-8)

Published Online
April 14, 2021
[http://dx.doi.org/10.1016/S2213-2600\(21\)00186-7](http://dx.doi.org/10.1016/S2213-2600(21)00186-7)

Published Online
April 26, 2021
[http://dx.doi.org/10.1016/S2213-2600\(21\)00209-5](http://dx.doi.org/10.1016/S2213-2600(21)00209-5)